UPM Pharmaceuticals is pleased to announce the promotion of two veteran team members to vice president positions, strengthening the company's leadership team as it continues its growth trajectory.
New Vice Presidents Named
Bridget Pforr has been promoted to Vice President of Project Management after 13 years of distinguished service with UPM. Her strategic vision and dedication to fostering strong client relationships have been fundamental to the company's success and expansion.
Narayan "Kani" Kanikkannan assumes the role of Vice President of Product Development & Technical Operations. His technical expertise and problem-solving capabilities have proven invaluable to UPM's existing programs and will be essential as the company onboards new clinical clients and programs.
Recognition of Excellence
Both promotions recognize the significant contributions these leaders have made to UPM's growth and success. Bridget's tenure at UPM has been marked by her ability to align project management strategies with client needs, ensuring successful program delivery and client satisfaction. Her deep institutional knowledge and relationship-building skills position her perfectly to lead the project management function.
Kani's technical acumen and innovative approach to problem-solving have been instrumental in advancing UPM's product development capabilities. His expertise will be particularly vital as the company expands its clinical services and takes on increasingly complex programs.
Supporting Continued Growth
These leadership appointments come at a time of significant expansion for UPM Pharmaceuticals. The promotions reflect the company's commitment to developing internal talent and recognizing the contributions of team members who have helped build the organization's strong foundation.
As UPM continues to grow its client base and expand its service offerings, having experienced leaders like Bridget and Kani in these critical roles ensures the company can maintain its high standards of quality and client service while pursuing new opportunities in the pharmaceutical development and manufacturing space.